StreetWatch: As Washington Puts a 100 Percent Tariff on Foreign Drones, the Magnet Inside Them Comes Into Focus
Washington just put a 100 percent tariff on the most sensitive foreign drones and certain parts. That is a magnet problem. Every rotor motor, gimbal, and actuator in a modern unmanned aircraft runs on rare earth permanent magnets. The tariff is telling every domestic drone builder to find non-China magnets, and to find them fast. Stack that on the January 1, 2027 Pentagon rule that bars Chinese-origin magnets in covered defense systems, and the shopping list is the same chemistry. Most of the...
2026-08-18 8:30 AM EDT
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It
Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, generated $71.3 million of global revenue during the second quarter of 2026, including $51.0 million in the United States and representing a 19% sequential quarter increase in global sales. Palatin Technologies (NASDAQ: PTN) previously advanced the...
2026-08-06 9:40 AM EDT
StreetWatch: As Federal Funding Floods the Drone Market, Quantum Cyber Is Assembling a Next Generation Platform
Washington's drone strategy is accelerating on two fronts: pouring unprecedented capital into domestic production while aggressively targeting the supply chains behind Iranian UAVs. Quantum Cyber N.V. (NASDAQ: QUCY) appears positioned squarely within that emerging policy corridor. Through its U.S. subsidiary, the company has acquired an equipped 50,000-square-foot manufacturing facility in Connecticut, established a federal procurement vehicle, and outlined plans to produce up to 100,000...
2026-08-03 10:51 AM EDT
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco Pharmaceutical Group. Report highlights: Nuvectis Pharma (NASDAQ: NVCT) recently secured worldwide rights outside China to NXP100, a potentially best-in-class once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), along with oncology asset NXP200, from Haisco Pharmaceutical Group. The...
2026-07-14 10:40 AM EDT